KalVista Pharmaceuticals (KALV) Corporate Presentation summary

Mission and strategy

• Focus on developing therapies for rare diseases with high unmet needs, starting with hereditary angioedema (HAE).

• Strategy includes leveraging global infrastructure to develop, acquire, or in-license additional innovative therapies.

EKTERLY product overview

• EKTERLY is the first and only oral on-demand therapy for HAE, approved in seven major global markets.

• Indicated for acute HAE attacks in patients aged 12 and older, with planned expansion to ages 2-11 in 2027.

• Demonstrates rapid, sustained relief and a strong safety profile.

HAE disease and treatment landscape

• HAE is a rare, lifelong disease with unpredictable, potentially life-threatening swelling attacks.

• Injectable on-demand therapies are underutilized, with significant delays in treatment and many attacks going untreated.

• Prior to EKTERLY, management relied on parenteral treatments and long-term prophylaxis, often with high burden and cost.